Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*
Authors:
- Derek C. AngusDADerek C. Angus
- Walter T. Linde-ZwirbleWLWalter T. Linde-Zwirble
- Gilles ClermontGCGilles Clermont
- Daniel E. BallDBDaniel E. Ball
- Bruce R. BassonBBBruce R. Basson
- E. Wesley ElyEEE. Wesley Ely
- Pierre-Francois LaterrePLPierre-Francois Laterre
- Jean-Louis VincentJVJean-Louis Vincent
- Gordon BernardGBGordon Bernard
- Ben van HoutBHBen van Hout
- 1 January 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 31 (1) , 1-11
Abstract
To assess the cost-effectiveness of drotrecogin alfa (activated) therapy, which was recently shown to reduce mortality in severe sepsis. Estimates of effectiveness and resource use were based on data collected prospectively as part of a multicenter international trial. Estimates of hospital costs were based on a subset of the patients treated in the United States (33% of all enrolled patients). Lifetime projections were modeled from published sources and tested in sensitivity analyses. Analyses were conducted from the United States societal perspective, limited to healthcare costs, and using a 3% annual discount rate. A total of 164 medical institutions in 11 countries. Adults > or = 18 yrs of age with severe sepsis Eligible patients were randomly assigned to receive a 96-hr intravenous infusion of drotrecogin alfa (activated) at 24 microg/kg/hr (n = 850) or placebo (n = 840). Base Case: incremental short-term (days 1-28) healthcare costs per day-28 survivor; Panel on Cost-Effectiveness in Health and Medicine Reference Case: incremental lifetime healthcare costs per quality-adjusted life-year. Over the first 28 days (short-term Base Case), drotrecogin alfa (activated) increased the costs of care by $9,800 and survival by 0.061 lives saved per treated patient. Thus, drotrecogin alfa (activated) cost $160,000 per life saved (with 84.7% probability that ratio is <$250,000 per life saved). Projected to lifetime (lifetime Reference Case), drotrecogin alfa (activated) increased the costs of care by $16,000 and quality-adjusted survival by 0.33 quality-adjusted life-years per treated patient. Thus, drotrecogin alfa (activated) cost $48,800 per quality-adjusted life-year (with 82% probability that ratio is <$100,000 per quality-adjusted life-year). Estimates were generally robust to sensitivity analyses, although cost-effectiveness deteriorated to >$100,000 per quality-adjusted life-year if survivors lived or = 25 and was cost-ineffective when limited to patients with a score <25. Drotrecogin alfa has a cost-effectiveness profile similar to that of many well-accepted healthcare strategies and below commonly quoted thresholds.Keywords
This publication has 33 references indexed in Scilit:
- Understanding Costs and Cost-Effectiveness in Critical Care: Report from the Second American Thoracic Society Workshop on Outcomes ResearchAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of careCritical Care Medicine, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Changes of the hemostatic network in critically ill patients-Is there a difference between sepsis, trauma, and neurosurgery patients?Critical Care Medicine, 2000
- The Journal's Policy on Cost-Effectiveness AnalysesNew England Journal of Medicine, 1994
- Epidemic Meningococcemia and Purpura Fulminans with Induced Protein C DeficiencyClinical Infectious Diseases, 1993
- Time Course of Hemostatic Abnormalities in Sepsis and its Relation to OutcomeChest, 1993
- American College of Chest Physicians/Society of Critical Care Medicine Consensus ConferenceCritical Care Medicine, 1992
- Septic Shock, Multiple Organ Failure, and Disseminated Intravascular CoagulationChest, 1992
- The protein C anticoagulant pathway.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992